New drug shows promise against kidney transplant rejection
A clinical trial revealed promising results regarding the drug "Tigoprobart," which is considered a candidate for improving the treatment of organ rejection after kidney transplants and reducing side effects. The drug showed improvements in kidney function and decreased rates of organ rejection compared to the standard treatment "Tacrolimus." The study lasted 12 months and focused on kidney transplant patients, reporting a significant reduction in failure cases and side effects, which could contribute to enhancing patients' lives and the quality of their care.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading